JP2010535012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010535012A5 JP2010535012A5 JP2009551102A JP2009551102A JP2010535012A5 JP 2010535012 A5 JP2010535012 A5 JP 2010535012A5 JP 2009551102 A JP2009551102 A JP 2009551102A JP 2009551102 A JP2009551102 A JP 2009551102A JP 2010535012 A5 JP2010535012 A5 JP 2010535012A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- egfr
- composition
- separate
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 10
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 2
- 102000045108 human EGFR Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 238000005580 one pot reaction Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200700317 | 2007-03-01 | ||
| DKPA200700317 | 2007-03-01 | ||
| US90477307P | 2007-03-05 | 2007-03-05 | |
| US60/904,773 | 2007-03-05 | ||
| DKPA200701016 | 2007-07-10 | ||
| DKPA200701016 | 2007-07-10 | ||
| US92972707P | 2007-07-11 | 2007-07-11 | |
| US60/929,727 | 2007-07-11 | ||
| PCT/DK2008/050047 WO2008104183A2 (en) | 2007-03-01 | 2008-02-27 | Recombinant anti-epidermal growth factor receptor antibody compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010535012A JP2010535012A (ja) | 2010-11-18 |
| JP2010535012A5 true JP2010535012A5 (cg-RX-API-DMAC7.html) | 2011-04-14 |
| JP5726417B2 JP5726417B2 (ja) | 2015-06-03 |
Family
ID=39495833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009551102A Active JP5726417B2 (ja) | 2007-03-01 | 2008-02-27 | 組み換え抗上皮成長因子受容体抗体組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7887805B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2132229B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5726417B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101805140B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101675075B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008221118B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0808551B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2676049C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2132229T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2582386T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1197252A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL199725A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2009008909A (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ597466A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2132229T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2013119724A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI426083B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008104183A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| DK2132229T3 (en) | 2007-03-01 | 2016-06-20 | Symphogen As | Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS |
| HRP20110686T1 (hr) * | 2007-03-01 | 2011-10-31 | Symphogen A/S | Postupak kloniranja srodnih protutijela |
| JP2008289483A (ja) * | 2007-05-25 | 2008-12-04 | Symphogen As | 真核生物系において発現可能な形質転換体のスクリーニング |
| WO2009030239A1 (en) * | 2007-09-06 | 2009-03-12 | Genmab A/S | Novel methods and antibodies for treating cancer |
| WO2009086411A2 (en) * | 2007-12-27 | 2009-07-09 | Abbott Laboratories | Negative mimic antibody for use as a blocking reagent in bnp immunoassays |
| WO2010022738A1 (en) * | 2008-08-29 | 2010-03-04 | Symphogen A/S | Method for cloning avian-derived antibodies |
| WO2010022736A2 (en) * | 2008-08-29 | 2010-03-04 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| WO2010040356A1 (en) * | 2008-10-06 | 2010-04-15 | Symphogen A/S | Method for identifying and selecting drug candidates for combinatorial drug products |
| FR2942928B1 (fr) | 2009-03-03 | 2011-04-01 | Alcatel Lucent | Procede et systeme de gestion multicriteres de notifications de presence |
| FR2945538B1 (fr) * | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| US8821879B2 (en) | 2009-09-04 | 2014-09-02 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
| JP2013507603A (ja) * | 2009-10-09 | 2013-03-04 | シムフォゲン・アクティーゼルスカブ | 署名ペプチドおよび質量分析による混合物中の個々の組換えタンパク質の多重定量化 |
| WO2011106707A2 (en) * | 2010-02-26 | 2011-09-01 | Human Genome Sciences, Inc. | Antibodies that specifically bind to dr3 |
| US8609095B2 (en) | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
| EP2563393B1 (en) | 2010-04-26 | 2016-06-08 | Abraxis BioScience, LLC | Sparc binding antibodies and uses thereof |
| WO2011140151A1 (en) * | 2010-05-04 | 2011-11-10 | Dyax Corp. | Antibodies against epidermal growth factor receptor (egfr) |
| EP2566512A1 (en) * | 2010-05-04 | 2013-03-13 | Merrimack Pharmaceuticals, Inc. | Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
| WO2012018260A1 (en) * | 2010-08-05 | 2012-02-09 | Universiteit Utrecht Holding B.V. | Epidermal growth factor receptor targeted immune therapy |
| JP5828902B2 (ja) | 2010-10-29 | 2015-12-09 | イミュノジェン， インコーポレイテッド | 非拮抗性ｅｇｆｒ結合分子およびその免疫複合体 |
| CN103298489A (zh) * | 2010-10-29 | 2013-09-11 | 伊缪诺金公司 | 新型egfr结合分子及其免疫偶联物 |
| MX347981B (es) * | 2010-11-01 | 2017-05-22 | Symphogen As | Composicion de anticuerpos pan-her. |
| US9155802B2 (en) * | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| PT2663579T (pt) | 2011-01-14 | 2017-07-28 | Univ California | Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização |
| PT2668209T (pt) * | 2011-01-24 | 2021-04-07 | Gilead Sciences Inc | Anticorpos seletivos para células que apresentam egfr em alta densidade |
| CN108220297A (zh) | 2011-03-09 | 2018-06-29 | 细胞信号科技公司 | 用于生成单克隆抗体的方法和试剂 |
| BR112013022882A2 (pt) | 2011-03-11 | 2016-12-20 | Merrimack Pharmaceuticals Inc | uso de inibidores de receptores da família egfr no tratamento de cânceres de mama hormônio-refratários |
| US20150231238A1 (en) | 2011-03-15 | 2015-08-20 | Merrimack Pharmaceuticals, Inc. | Overcoming resistance to erbb pathway inhibitors |
| US20120258502A1 (en) * | 2011-04-08 | 2012-10-11 | Vinod Pandiripally | Method of producing recombinant plasmid dna using substantially solid growth medium |
| US8691231B2 (en) * | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| EP2794010A4 (en) | 2011-11-21 | 2015-10-21 | Immunogen Inc | METHOD OF TREATING TUMORS RESISTANT TO EGFR THERAPIES BY A CYTOTOXIC EGFR-AGENT ANTIBODY CONJUGATE |
| CN104411717A (zh) * | 2012-01-09 | 2015-03-11 | 斯克利普斯研究所 | 具有超长cdr3s的人源化抗体 |
| KR101933990B1 (ko) | 2012-05-02 | 2018-12-31 | 심포젠 에이/에스 | 인간화 ｐａｎｈｅｒ 항체 조성물 |
| WO2014038025A1 (ja) * | 2012-09-05 | 2014-03-13 | Ｓｃｉｖａｘ株式会社 | 細胞の上皮性維持に作用する物質のスクリーニング方法 |
| WO2014063206A1 (en) * | 2012-10-26 | 2014-05-01 | The University Of Queensland | Methods for classifying tumors and uses therefor |
| CN102993305B (zh) * | 2012-11-16 | 2015-05-13 | 上海赛伦生物技术有限公司 | 人源抗人表皮生长因子受体抗体及其编码基因与应用 |
| US9856319B2 (en) * | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
| CN104059148B (zh) * | 2013-03-18 | 2016-09-07 | 回而生医药科技（北京）有限公司 | 人源化抗人表皮生长因子受体抗体及其应用 |
| HK1226081A1 (zh) * | 2013-09-12 | 2017-09-22 | Halozyme, Inc. | 修饰的抗表皮生长因子受体抗体及其使用方法 |
| EP3096787A4 (en) * | 2014-01-22 | 2018-02-07 | The Board of Trustees of the Leland Stanford Junior University | Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy |
| GB201402591D0 (en) | 2014-02-14 | 2014-04-02 | Memo Therapeutics Ag | Method for recovering two or more genes, or gene products, encoding an immunoreceptor |
| WO2015148479A1 (en) * | 2014-03-26 | 2015-10-01 | Siemens Healthcare Diagnostics Inc. | Luminescent oxygen channeling immunoassay utilizing three antibodies and methods of production and use thereof |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| MA40968A (fr) * | 2014-10-31 | 2017-10-04 | Formation Biologics Inc | Polythérapie à base d'anticorps anti-egfr |
| JP6895380B2 (ja) | 2015-02-06 | 2021-06-30 | ナショナル ユニバーシティ オブ シンガポール | 治療免疫細胞の有効性を改良するための方法 |
| CA2983890A1 (en) | 2015-04-24 | 2016-10-27 | Merrimack Pharmaceuticals, Inc. | Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies |
| CA3011949A1 (en) | 2016-03-15 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
| CN109475627B (zh) * | 2016-05-26 | 2023-01-06 | 齐鲁普吉湾生物治疗公司 | 抗体混合物 |
| CN109843327B (zh) | 2016-07-07 | 2022-05-13 | 小利兰·斯坦福大学托管委员会 | 抗体佐剂缀合物 |
| CN118562882B (zh) | 2016-11-22 | 2025-08-08 | 新加坡国立大学 | 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体 |
| KR102702552B1 (ko) * | 2016-12-23 | 2024-09-03 | 비스테라, 인크. | 결합 폴리펩타이드 및 이의 제조 방법 |
| CA3054381A1 (en) * | 2017-02-22 | 2018-08-30 | University Of Saskatchewan | Egfr-binding agents and uses thereof |
| WO2018166119A1 (zh) * | 2017-03-14 | 2018-09-20 | 北京伟峰益民科技有限公司 | 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用 |
| US20190038733A1 (en) | 2017-08-10 | 2019-02-07 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| TW201925230A (zh) | 2017-08-30 | 2019-07-01 | 丹麥商賽門弗鎮公司 | 以抗egfr療法治療癌症的組成物及方法 |
| WO2019114793A1 (zh) * | 2017-12-13 | 2019-06-20 | 凯惠科技发展(上海)有限公司 | 一种egfr抗体及其制备方法和应用 |
| WO2019147863A2 (en) * | 2018-01-25 | 2019-08-01 | Pdi Therapeutics, Inc. | Mica/b antibodies and methods of use |
| AU2019275076B2 (en) | 2018-05-23 | 2024-12-19 | National University Of Singapore | Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies |
| US11274035B2 (en) | 2019-04-24 | 2022-03-15 | X-Celeprint Limited | Overhanging device structures and related methods of manufacture |
| US12162747B2 (en) | 2018-12-03 | 2024-12-10 | X-Celeprint Limited | Enclosed cavity structures |
| US10456776B1 (en) | 2019-02-21 | 2019-10-29 | King Saud University | Method of fabricating a photocatalyst for water splitting |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| CN111018990A (zh) * | 2020-02-10 | 2020-04-17 | 张喜田 | 一种新型的重组抗表皮生长因子受体单克隆抗体及其应用 |
| IL311736A (en) | 2021-10-04 | 2024-05-01 | Servier Lab | Cancer therapy targeting nkg2a |
| AR127893A1 (es) | 2021-12-10 | 2024-03-06 | Servier Lab | Terapia del cáncer dirigida a egfr |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5459061A (en) | 1990-01-26 | 1995-10-17 | W. Alton Jones Cell Science Center, Inc. | Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor |
| ES2204890T3 (es) * | 1991-03-06 | 2004-05-01 | Merck Patent Gmbh | Anticuerpos monoclonales humanizados. |
| EP0655924A4 (en) | 1992-06-30 | 1996-09-11 | Oncologix Inc | A COMBINATION OF MONOCLONAL ANTIBODIES AGAINST erbB-2 AND METHOD FOR THEIR USE. |
| GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US7201905B2 (en) | 2000-03-23 | 2007-04-10 | Greenville Hospital System | Bi-functional cancer treatment agents |
| EP1278851B1 (en) * | 2000-05-19 | 2006-01-18 | Scancell Limited | Humanised antibodies to the epidermal growth factor receptor |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| BR0207283A (pt) * | 2001-02-19 | 2004-08-17 | Merck Patent Gmbh | Anticorpos anti-egfr modificados com imunogenicidade reduzida |
| ATE446317T1 (de) | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
| KR100945108B1 (ko) | 2001-06-13 | 2010-03-02 | 젠맵 에이/에스 | 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체 |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| US7662374B2 (en) | 2001-08-03 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbB family members and methods of use thereof |
| EP1482043A4 (en) * | 2002-03-01 | 2005-08-10 | Japan Enviro Chemicals Ltd | FOR BINDING TO ENVIRONMENTAL MORNES, PROTEINS AND METHOD FOR THE PRODUCTION THEREOF |
| US20060002934A1 (en) | 2002-05-15 | 2006-01-05 | Birgit Luber | Egf receptor antagonists in the treatment of gastric cancer |
| JP2006508899A (ja) | 2002-05-20 | 2006-03-16 | アブジエニツクス・インコーポレイテツド | ＥＧＦｒに対する抗体を使用する腎癌の治療方法 |
| AU2003273218C1 (en) | 2002-07-15 | 2019-01-17 | F. Hoffmann - La Roche Ag | Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies |
| PT1523496E (pt) | 2002-07-18 | 2011-09-29 | Merus B V | Produção de misturas de anticorpos de forma recombinante |
| PL210545B1 (pl) * | 2002-10-10 | 2012-01-31 | Merck Patent Gmbh | Kompozycja farmaceutyczna i zestaw farmaceutyczny zawierające przeciwciała ukierunkowane na receptory ERB-B1 oraz ich zastosowanie do otrzymywania leku do leczenia nowotworów |
| EA013225B1 (ru) | 2003-01-07 | 2010-04-30 | Симфоген А/С | Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток |
| US20060275766A1 (en) | 2003-01-07 | 2006-12-07 | Haurum John S | Method for manufacturing recombinant polyclonal proteins |
| CA2450289A1 (en) | 2003-03-20 | 2005-05-19 | Imclone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| AT500651B9 (de) | 2003-05-27 | 2010-04-15 | Altropus Gmbh | Aktiv immunisierender antikörper |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| WO2005071075A1 (ja) | 2004-01-23 | 2005-08-04 | Green Peptide Co., Ltd. | 上皮細胞増殖因子受容体（egfr）由来ペプチド |
| WO2006009694A2 (en) | 2004-06-14 | 2006-01-26 | Imclone Sysetms Incorporated | Crystal of egfr extracellular domain and cetuximab fab fragment and uses thereof |
| EP2053408B1 (en) | 2004-07-20 | 2012-03-07 | Symphogen A/S | A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
| KR20070038556A (ko) | 2004-07-20 | 2007-04-10 | 심포젠 에이/에스 | 항-ｒｈｅｓｕｓ ｄ 재조합 폴리클로날 항체 및 이의 제조방법 |
| CA2592177A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| US20070009972A1 (en) | 2005-02-16 | 2007-01-11 | Ginger Chao | Epidermal growth factor receptor polypeptides and antibodies |
| CA2596133C (en) | 2005-02-23 | 2016-11-15 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
| US7981605B2 (en) | 2005-02-24 | 2011-07-19 | Amgen Inc. | Epidermal growth factor receptor mutations |
| US20060216288A1 (en) | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
| WO2006110478A2 (en) | 2005-04-11 | 2006-10-19 | Novartis Ag | Mutations and polymorphisms of epidermal growth factor receptor |
| RU2007141067A (ru) | 2005-04-14 | 2009-05-20 | Мерк Патент ГмбХ (DE) | Терапия с помощью антител к egfr, основанная на повышенном числе копий гена egfr в опухолевых тканях |
| WO2006116001A2 (en) | 2005-04-27 | 2006-11-02 | Welson Pharmaceuticals, Inc. | Antibodies for the treatment of cancers |
| CN104356236B (zh) * | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| MX2008000030A (es) * | 2005-07-11 | 2008-04-02 | Macrogenics Inc | Metodos para el tratamiento de enfermedad autoinmune utilizando anticuerpos anti-cd16a humanizados. |
| JP2009518320A (ja) | 2005-12-05 | 2009-05-07 | シュムフォウエン アクティーゼルスカブ | 抗オルトポックスウイルス組換えポリクローナル抗体 |
| US7498142B2 (en) * | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| KR20080113223A (ko) | 2006-03-06 | 2008-12-29 | 심포젠 에이/에스 | 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체 |
| HRP20110686T1 (hr) | 2007-03-01 | 2011-10-31 | Symphogen A/S | Postupak kloniranja srodnih protutijela |
| DK2132229T3 (en) * | 2007-03-01 | 2016-06-20 | Symphogen As | Recombinant anti-epidermal growth factor receptor-ANTIBODY COMPOSITIONS |
| JP2008289483A (ja) * | 2007-05-25 | 2008-12-04 | Symphogen As | 真核生物系において発現可能な形質転換体のスクリーニング |
| WO2010022736A2 (en) * | 2008-08-29 | 2010-03-04 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| US9155802B2 (en) * | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
-
2008
- 2008-02-27 DK DK08706941.5T patent/DK2132229T3/en active
- 2008-02-27 MX MX2009008909A patent/MX2009008909A/es active IP Right Grant
- 2008-02-27 MX MX2011011163A patent/MX338151B/es unknown
- 2008-02-27 ES ES08706941.5T patent/ES2582386T3/es active Active
- 2008-02-27 NZ NZ597466A patent/NZ597466A/xx not_active IP Right Cessation
- 2008-02-27 AU AU2008221118A patent/AU2008221118B2/en active Active
- 2008-02-27 WO PCT/DK2008/050047 patent/WO2008104183A2/en not_active Ceased
- 2008-02-27 EP EP08706941.5A patent/EP2132229B1/en active Active
- 2008-02-27 NZ NZ578943A patent/NZ578943A/xx unknown
- 2008-02-27 PL PL08706941.5T patent/PL2132229T3/pl unknown
- 2008-02-27 KR KR1020167031076A patent/KR101805140B1/ko not_active Expired - Fee Related
- 2008-02-27 JP JP2009551102A patent/JP5726417B2/ja active Active
- 2008-02-27 KR KR1020097020519A patent/KR101676622B1/ko active Active
- 2008-02-27 CN CN200880006835.0A patent/CN101675075B/zh active Active
- 2008-02-27 EP EP13187455.4A patent/EP2725036B1/en not_active Not-in-force
- 2008-02-27 CN CN201410211600.2A patent/CN104151430A/zh active Pending
- 2008-02-27 CA CA2676049A patent/CA2676049C/en active Active
- 2008-02-27 BR BRPI0808551-0A patent/BRPI0808551B1/pt active IP Right Grant
- 2008-02-29 TW TW097107005A patent/TWI426083B/zh active
- 2008-02-29 US US12/074,056 patent/US7887805B2/en active Active
-
2009
- 2009-07-07 IL IL199725A patent/IL199725A/en active IP Right Grant
-
2010
- 2010-11-12 US US12/945,495 patent/US20110129855A1/en not_active Abandoned
- 2010-11-12 US US12/945,527 patent/US8414896B2/en active Active
-
2011
- 2011-12-08 IL IL216850A patent/IL216850A/en active IP Right Grant
-
2013
- 2013-04-26 RU RU2013119724/10A patent/RU2013119724A/ru not_active Application Discontinuation
-
2014
- 2014-10-29 HK HK14110853.9A patent/HK1197252A1/en unknown